SCHEMBL2173695

SCHEMBL2173695

CN1C(=O)c2ccccc2C1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
ATM Q13315 1/20 0.56
RAB9A P51151 5/20 0.51
ALDH1A1 P00352 4/20 0.51
HSD17B10 Q99714 1/20 0.51
NPC1 O15118 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
PKM P14618 3/20 0.49
TP53 P04637 2/20 0.49
STAT3 P40763 1/20 0.49
STAT1 P42224 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
TSHR P16473 1/20 0.48
LMNA P02545 2/20 0.47
HPGD P15428 1/20 0.47
KDM4E B2RXH2 2/20 0.46
GAA P10253 1/20 0.46
HTT P42858 2/20 0.44
FFAR1 O14842 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22623757 1.00 MEN1 (0.56) MEN1KMT2AATMRAB9AALDH1A1
SCHEMBL13206625 1.00 MEN1 (0.56) MEN1KMT2AATMRAB9AALDH1A1
SCHEMBL19255620 0.92 MEN1 (0.49) MEN1KMT2AATMRAB9AALDH1A1
SCHEMBL19003848 0.80 ALDH1A1 (0.49) MEN1KMT2AALDH1A1HSD17B10SMN1; SMN2
SCHEMBL8463734 0.80 RAB9A (0.49) MEN1KMT2AATMRAB9AALDH1A1
SCHEMBL8611610 0.80 RAB9A (0.49) MEN1KMT2AATMRAB9AALDH1A1
SCHEMBL9912528 0.78 ALDH1A1 (0.54) MEN1KMT2AATMRAB9AALDH1A1
SCHEMBL22792110 0.78 GPR3 (0.60) MEN1KMT2AATMALDH1A1HSD17B10
SCHEMBL13704120 0.78 GPR3 (0.60) MEN1KMT2AATMALDH1A1HSD17B10
SCHEMBL13704044 0.78 GPR3 (0.60) MEN1KMT2AATMALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3183236-B1 METHOD FOR THE PRODUCTION OF 18F-LABELED ACTIVE ESTERS AND THEIR APPLICATION EXEMPLIFIED BY THE PREPARATION OF A PSMA-SPECIFIC PET-TRACER MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WSS (DE) 2022-04-20 EP disclosed
EP-2388003-B1 Colchicine derivatives CALIFORNIA PACIFIC MEDICAL CENTER (US) 2021-12-29 EP disclosed
US-20210316006-A1 PYRROLOBENZODIAZEPINE CONJUGATES MEDIMMUNE LIMITED (GB) 2021-10-14 US disclosed
WO-2021106627-A1 POLYIMIDE, POLYIMIDE RESIN FILM, MULTILAYER BODY AND FLEXIBLE DEVICE 東レ株式会社 2021-06-03 WO disclosed
EP-3207929-B1 COLCHICINE DERIVATIVES FOR THE TREATMENT OF CANCER CALIFORNIA PACIFIC MEDICAL CENTER (US) 2021-05-26 EP disclosed
US-10894239-B2 Dispersant, dispersion composition, and fibrous sheet MEISEI CHEMICAL WORKS, LTD. (JP) 2021-01-19 US disclosed
EP-3279236-B1 BIODEGRADABLE POLYETHYLENE GLYCOL DERIVATIVE HAVING CYCLIC BENZYLIDENE ACETAL LINKER NOF CORP (JP) 2021-01-06 EP disclosed
EP-3377510-B1 GALNAC CLUSTER PHOSPHORAMIDITE HOFFMANN LA ROCHE (CH) 2020-12-02 EP disclosed
US-20200362177-A1 FLUOROPOLYMER COMPOSITION SOLVAY SPECIALTY POLYMERS IT (US) 2020-11-19 US disclosed
US-20200309782-A1 INTRACELLULAR DELIVERY VEHICLE KIRIN HOLDINGS KABUSHIKI KAISHA (JP) 2020-10-01 US disclosed
EP-1528923-A1 N-((3-OXO-2,3-DIHYDRO-1H-ISOINDOL-1-YL)ACETYL)GUANIDINE DERIVATIVES AS NHE1-INHIBITORS FOR THE TREATMENT OF INFARCTION AND ANGINA PECTORIS Aventis Pharma Deutschland GmbH (DE) 2005-05-11 EP disclosed
US-20050051438-A1 Electrosynthesis of organic compounds QUEEN'S UNIVERSITY OF BELFAST, THE (GB) 2005-03-10 US disclosed
EP-1404896-A2 ELECTROSYNTHESIS OF ORGANIC COMPOUNDS The Queen's University of Belfast (GB) 2004-04-07 EP disclosed
US-20040048916-A1 Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them AVENTIS PHARMA DEUSCHLAND GMBH (DE) 2004-03-11 US disclosed
WO-2003101450-A1 N- ((3-OXO2, 3-DIHYDRO-1H-ISOINDOL-1-YL) ACETYL) GUANIDINE DERIVATIVES AS NHE-1 INHIBITORS FOR THE TREATMENT OF INFARCTION AND ANGINA PECTORIS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-12-11 WO disclosed
WO-2003004727-A2 ELECTROSYNTHESIS OF ORGANIC COMPOUNDS THE QUEEN'S UNIVERSITY OF BELFAST (GB) 2003-01-16 WO disclosed
EP-0734383-B1 CYCLIC AMIDE DERIVATIVES AS NEUROKININ A ANTAGONISTS ASTRAZENECA AB (SE) 2002-07-24 EP disclosed
US-5965576-A Cyclic amide derivatives for treating asthma ZENECA LIMITED (GB) 1999-10-12 US disclosed
US-5705505-A Cyclic amide derivatives for treating asthma ZENECA LIMITED (GB) 1998-01-06 US disclosed
US-5589489-A Cyclic amide derivatives for treating asthma ZENECA LIMITED (GB) 1996-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200309782-A1 INTRACELLULAR DELIVERY VEHICLE CHERP, ACTB, GOLT1B MEN1 2207/4885KMT2A 4632/4885ATM 3692/4885
US-20210316006-A1 PYRROLOBENZODIAZEPINE CONJUGATES BCR, MCL1, CD79B MEN1 2781/4885KMT2A 1395/4885ATM 4013/4885
US-20040048916-A1 Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them TNNI3, NDUFB3, NDUFB11 MEN1 3718/4885KMT2A 4806/4885ATM 2652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.